Skip to main content

Cellectar Biosciences, Inc.

CLRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001279704

No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Cellectar Biosciences, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of CLRB: Q4 2021 compared with Q1 2022
MeasureQ4 2021Of which not filed for Q1 2022Q1 2022Change
Holders42132−9
Shares6.60M4006.82M+226.1K (+3.4%)
Value$4.38M$0$4.69M+$312.0K (+7.1%)

1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (1)

Institutions that held Cellectar Biosciences, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to CLRB in Q1 2022
InstitutionSharesValue% of portfolio
IFP Advisors, Inc5––

Sold out (10)

Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of CLRB in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Citadel Advisors LLC164,576$109.0K
Two Sigma Investments, LP65,086$43.0K
Susquehanna International Group, LLP50,256$33.0K
Price T Rowe Associates Inc41,700$28.0K
Virtu Financial LLC37,497$25.0K
Northwestern Mutual Wealth Management Co20,000$13.0K
Two Sigma Securities, LLC14,223$9.00K
Jane Street Group, LLC13,979$9.00K
Bank of America Corp106$0
Rockefeller Capital Management L.P.1,000$0

Not filed for Q1 2022 yet (1)

Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CLRB in Q4 2021 that haven't filed for Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Harbour Investments, Inc.400$0